Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04406831 · ClinicalTrials.gov registry record
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
A clinical trial of Pancreatic Ductal Adenocarcinoma and Pancreatic Neoplasms, sponsored by Nuvance Health.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT04406831 is a study of Pancreatic Ductal Adenocarcinoma and Pancreatic Neoplasms that is actively recruiting participants, run by Nuvance Health. The registered enrollment target is 200 participants, below the 598-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04406831, a study of Pancreatic Ductal Adenocarcinoma and Pancreatic Neoplasms, is actively recruiting participants, sponsored by Nuvance Health.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blood/serum of patients with pancreatic cancer may be important to the early diagnosis of the disease. Furthermore, the investigators hypothesize that miRNA detection in PC patients will yield prognostic information and help predict the response to treatment.
Conditions Studied
Interventions
- PROCEDURE Blood draw
Study Locations (1)
Connecticut
- Nuvance Health - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-04 |
| Est. Completion | 2027-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04406831
The ClinicalTrials.gov registry entry for NCT04406831 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (67% lower). The listed sponsor is Nuvance Health, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT04406831 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04406831 about?
NCT04406831 is a clinical study titled "The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer". Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer. The investigators hypothesize that the detection of certain miRNAs present in the blo...
What is the current status of trial NCT04406831?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2015-04. Estimated completion is 2027-04.
What conditions does trial NCT04406831 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Stage IV, Pancreatic Cancer Stage III.
What interventions are being tested in trial NCT04406831?
The interventions under investigation include: Blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT04406831?
This trial is sponsored by Nuvance Health, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04406831 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
RECRUITING
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.